mCRPC Patients Receiving (225)Ac-PSMA-617 Therapy in the Post–Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis

(225)Ac-PSMA-617, targeting the prostate-specific membrane antigen (PSMA), which is overexpressed on prostate cancer cells, has shown a remarkable therapeutic efficacy in heavily pretreated patients with metastatic castration-resistant prostate carcinoma (mCRPC). Here, we report on treatment outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Sathekge, Mike, Bruchertseifer, Frank, Vorster, Mariza, Lawal, Ismaheel O., Knoesen, Otto, Mahapane, Johncy, Davis, Cindy, Mdlophane, Amanda, Maes, Alex, Mokoala, Kgomotso, Mathabe, Kgomotso, Van, Christophe, de Wiele, Morgenstern, Alfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2022
Materias:
Featured Article of the Month
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536711/
https://www.ncbi.nlm.nih.gov/pubmed/35177427
http://dx.doi.org/10.2967/jnumed.121.263618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536711/
https://www.ncbi.nlm.nih.gov/pubmed/35177427
http://dx.doi.org/10.2967/jnumed.121.263618

Ejemplares similares